ShareValue.ai

ShareValue scores for CELZ: Valuation 51, Quality 48, Growth 41, Health 66.

Creative Medical Technology Holdings Inc logo

CELZ
NASDAQ

Creative Medical Technology Holdings Inc

$1.09(-5.22%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

6% to 16%
Valuation
51
Fair Value
Price vs Value
Quality
48
Moderate
Business Strength
Growth
41
Moderate
Revenue & Earnings
Health
66
Moderate
Financial Stability
Momentum
65
Bullish
Price Trend

Company Details

About

Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DDT), a allogenic human perinatal tissue derived cell program, ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, which is phase 2, for the treatment of type 1 diabetes; AlloStemSpine (CELZ 201 ADAPT), which is phase 2, for the treatment of chronic lower back pain; Alova, a platform to treat infertility as a result of premature ovarian failure; StemSpine, a regenerative stem cell procedure to treat degenerative disc disease; OvaStem, a stem cell therapy for premature ovarian failure; CaverStem for erectile dysfunction treatment; and FemCelz for female sexual function treatment. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona. Address: 211 East Osborn Road, Phoenix, AZ, United States, 85012

Score Analysis

AI Investment Thesis

Data as of:Jul 9, 2026
|
Last calculated:Jul 9, 2026